New drug aims to stop blood clots during dialysis

NCT ID NCT07201467

Recruiting now Disease control Sponsor: Suzhou Alphamab Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a drug called KN060 in 12 adults with end-stage kidney disease who are on regular hemodialysis. The goal is to see if KN060 is safe and can prevent blood clots from forming in the dialysis machine or the patient's blood vessels. Participants will receive the drug every two weeks for 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KN060 (a drug to prevent blood clots)
What this could lead to: If successful, KN060 could help prevent dangerous blood clots in dialysis machines and fistulas, making dialysis safer for kidney patients.
What could go wrong: This is a very early, small trial (12 people) focused on safety. The drug may not work as hoped, and side effects like bleeding are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE REQUIRING HAEMODIALYSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

END-STAGE RENAL DISEASE REQUIRING HAEMODIALYSIS

Contacts and locations

Locations

Peking University People's Hospital
RECRUITING

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.